Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for metabolic clues to boost lung cancer immunotherapy

NCT ID NCT07637474

Knowledge-focused Sponsor: Regina Elena Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the body's metabolism might influence whether immunotherapy drugs work in people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal is to find biological markers that predict response and discover new ways to make immunotherapy more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify which lung cancer patients will benefit from immunotherapy and point to new drug targets to overcome resistance.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly help participants. Results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering from NSCLC lung cancer

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Histological diagnosis of advanced stage NSCLC * Histotype adenocarcinoma and squamous carcinoma * ECOG PS \<2 * Known PDL-1 stage * Measurable disease * Availability of tumor tissue * No evidence of molecular drivers * Written informed consent (to the study and data processing) For the second cohort in addition to the precedents it is included * Diagnosis of limited or locally advanced NSCLC deemed resectable For the third cohort in addition to the precedents it is included * patients candidates for surgery for non-small cell lung cancer Exclusion Criteria: * Contraindications to immunotherapy * Unavailability of tumor tissue * Histotype with neuroendocrine or mixed component For the second cohort * Contraindication to immunotherapy * Histotype with neuroendocrine or mixed component * Locally advanced disease candidate for concomitant chemo-radiotherapy treatment For the third cohort * previously treated patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS National Cancer institute

    RECRUITING

    Rome, Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.